NACDS' online maps display state-by-state status of action amid COVID-19NACDS’ online maps show further action is needed to remove barriers to pharmacy patient care immediately. Novartis terminates sale of Sandoz U.S. generic oral solids, dermatology portfolio to AurobindoSandoz will continue to operate its oral solids and dermatology business as part of the Sandoz U.S. business. NACDS praises new Indiana law as boon for access to pharmacy services A new Indiana law allows a pharmacist to substitute a therapeutic alternative for epinephrine products. NCPA survey: Pharmacists back access to experimental COVID-19 treatment Ninety percent of local pharmacists are reporting a shortage of hydroxychloroquine, according to an NCPA survey. NACDS praises new Indiana law as vital for patient access and pharmacy viability Senate Bill 241 will help ensure that pharmacies are more fairly and properly reimbursed. NACDS praises Administration's recommendations to governors to empower pharmacists during COVID-19 NACDS praised Secretary of HHS Alex Azar's letter to the nation’s governors asking for assistance to extend the capacity of the healthcare workforce to address the pandemic. Mylan voluntarily waives marketing exclusivity for generic Kaletra Mylan will enable generic applicants to be eligible for FDA approval if Kaletra is found effective in treating COVID-19. 111 industry orgs urge government to maintain product supply, workforce NACDS is among 111 organizations urging government leaders at all levels to address barriers to the COVID-19 response. FDA institutes shortened approval pathway for biosimilars The FDA has enacted a shortened regulatory pathway for certain biologics, which will allow for faster approvals and increased competition. Generic drug patent cases disrupted by COVID-19 The 30-month stay deadline surrounding generic drug patent disputes is being hampered by courts limiting access and attorneys cutting back on travel. First Previous 65 66 67 68 69 Next Last
